A New Indication for Esketamine Nasal Spray (Spravato)
Date: September 21, 2020
Issue #:
1607Summary:
Esketamine (Spravato– Janssen), an intranasal
N-methyl-D-aspartate (NMDA) receptor antagonist
that was previously approved by the FDA for treatmentresistant
depression,1 has now been approved for
treatment of depressive symptoms in adults with
major depressive disorder (MDD) and acute suicidal
ideation or behavior. E sketamine is the S-enantiomer
of the anesthetic ketamine (Ketalar, and generics).
It is the first drug to be approved for this indication.
Most clinical trials of antidepressants have excluded
patients with acute suicidal ideation.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research
More News: Anesthesia | Anesthesiology | Clinical Trials | Depression | Drugs & Pharmacology | Suicide